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Acne	 is	one	of	 the	most	 common	dermatological	diseases	
seen	 by	 dermatologists	 in	 Latin	America,	 Spain	 and	 Portugal,	 as	
well	as	in	the	rest	of	the	world.	It	is	a	chronic	inflammatory	process	
that	 needs	 to	 be	 treated	 early	 and	 effectively	 to	decrease	 the	 risk	
of	physical	and	emotional	sequelae.	 In	this	article,	we	present	 the	
result of the consensus among a group of dermatologists from Latin 
America,	Spain	and	Portugal,	based	on	the	scientific	evidence	avail-










conducted	 in	 electronic	 format	 (e.g.	 Skype,	 e-mail)	 between	 2012	
and	2016,	questions	based	on	scientific	evidence	and	participants’	
experiences	were	circulated	until	a	consensus	was	reached,	which	
resulted	 in	 the	 therapeutic	 algorithm	 in	 Portuguese,	 Spanish	 and	
English	 adapted	 to	 the	 Iberian-Latin	American	 conditions,	 that	 is	
presented	in	this	paper	(Figures	1,	2	and	3).	
TOPICAL	TREATMENT
Topical treatment can be indicated as monotherapy or in com-
bination	with	systemic	antibiotics	or	hormonal	treatment,	depending	
on	 the	 type	of	acne.	The	majority	of	patients	with	comedonal	acne	












Considered	 the	first-line	 therapy	 for	 comedonal	 acne,	 ret-
inoids	 normalize	 infundibular	 keratinization,	 inhibit	 comedogen-
esis,	 have	 an	 anti-inflammatory	 action	 and	 also	 increase	 the	pen-
etration of other medications. They act by binding to cytoplasmic 




Toll-like	 receptors	 (TLR),	 the	 innate	 immunity,	 and	 the	 surface	of	
sebocytes	 that	 bind	 to	molecular	 patterns	 of	 the	microorganisms,	
in	this	case,	cell	wall	peptidoglycans	of	the	Propionibacterium acnes 
(P. acnes),	activating	signaling	pathways,	such	as	NF-κB,	with	pro-
duction	of	proinflammatory	cytokines.2 Two groups are available: 
first	 generation,	 tretinoin	or	 all-trans	 retinoic	 acid	 (concentrations	
of	0.025%,	0.05%	and	0.1%)	and	isotretinoin	or	13-cis-retinoic	acid	
(sparingly	used)	and	synthetic	retinoids,	adapalene	and	tazarotene,	
the latter not available in many countries. Tretinoin and adapalene 
are	classified	as	Class	C	and	Tazarotene	as	X	by	the	Food	and	Drug	
Administration	 (FDA)	 -	 the	 United	 States	 regulatory	 agency.	 Re-
cently	the	FDA	removed	the	prescription	need	for	adapalene	0.1%,	
based on a meta-analysis that showed no increase in the incidence of 
congenital	malformations,	abortion,	low	birth	weight	or	prematuri-
ty	in	women	who	used	adapalene	during	pregnancy.	For	tretinoin,	
the recommendation not to use during gestation was maintained.3 
Irritant	contact	dermatitis	 (erythema,	pruritus,	desquamation),	 in-
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 PB is an antimicrobial agent with activity against P. acnes by 
the	release	of	reactive	oxygen	species	(ROS),	and	mild	comedolytic	
effect.	There	is	no	description	of	PB-resistant	strains;	moreover,	its	
use in combination with topical or systemic antibiotics prevents and 




Topical antibiotics accumulate in the follicle and present an-
ti-inflammatory	and	antimicrobial	effect.	Its	use	as	monotherapy	is	
not	recommended,	but	combined	with	PB,	it	shows	increased	effica-
cy and decreased bacterial resistance.1
Fixed combinations
Fixed combinations have advantages over monotherapy be-
cause they act on several etiopathogenic factors. They have antimi-
crobial,	anti-inflammatory	and	comedolytic	activity	while	 increas-
ing	PB	penetration.	They	are	the	first	choice	for	mild	to	moderate	
papular-pustular acne. The available options are: PB with clinda-
mycin	 or	 erythromycin,	 tretinoin	 with	 clindamycin	 and	 PB	 with	
adapalene. There are two concentrations of adapalene combined 
with PB available in some countries: 0.1% for mild to moderate pus-
tular acne and 0.3% approved in the United States and indicated for 
moderate to severe forms. Use of a single product increases adher-








to	 moderate	 papular-pustular	 acne,	 particularly	 in	 patients	 with	
sensitive	and	darker	skin,	as	well	as	in	adult	acne	in	women.	AA	is	




acne treatment for years.1 Their indication is papular-pustular and 
mild nodular-cystic acne. They are effective due to their antibacteri-
al,	immunosuppressive,	but	fundamentally	by	their	anti-inflamma-
tory	actions.	OABs	should	be	used	from	6	to	12	weeks.	Their	effect	
depends	 on	 gastrointestinal	 permeability,	 absorption,	 distribution	
and	penetration	into	the	skin.	The	more	soluble	and	permeable	ones	
are	better	absorbed	and	distributed,	while	the	lipophilic	ones	pene-
trate better in the pilosebaceous follicle. P. acnes is the main bacteria 
involved in the etiopathogenesis of acne. It produces lipases that 
hydrolyze	 triglycerides,	 releasing	pro-inflammatory	 fatty	acids.	P. 
acnes is	recognized	by	TLR-2	and	4,	activating	the	NF-κB	pathways,	
with	production	of	IL-6	and	IL-8	by	follicular	keratinocytes	and	IL-8	
and	 IL-12	 by	macrophages	 and	AP-1,	 with	 production	 of	 matrix	
metalloproteinases	 (MMP)	 that	 degrade	 the	 dermal	 extracellular	
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day,	minocycline,	 100mg/day	and	 tetracycline	500mg	 twice	daily,	
are	the	most	used	OABs.	Erythromycin	1,000mg	per	day	is	recom-








ation with the use of topical PB and/or retinoid and improper ro-
tational	use.	Consequences	are	not	limited	to	P. acnes,	but	to	other	




Isotretinoin is effective and safe in the treatment of severe 




by P. acnes	and	reducing	inflammation	by	modulating	TLR-2	and	4.9 













adverse	 events	 are:	 cheilitis,	 xerosis	 cutis,	 facial	 dermatitis,	 nasal	
dryness,	epistaxis,	dry	eyes,	blepharoconjunctivitis	and	contact	lens	





To reduce this exacerbation the treatment should start with a daily 
low	dose,	combined	with	oral	corticosteroids	and	antibiotics	(except	
tetracyclines),	until	the	lesions	improve,	when	they	are	withdrawn	
and the dose of isotretinoin is increased. Other unpredictable events 
that are depending on dose and individual susceptibility are: eleva-
tion	of	liver	enzymes	and	triglycerides,	increase	of	serum	cholesterol	
LDL	fraction,	and	decreased	HDL	fraction	as	well	as	hematological	
changes. Laboratory monitoring is mandatory at baseline and after 
1	to	2	months.	If	tests	are	abnormal,	they	should	be	repeated	every	
month.10 Teratogenicity is the most serious and irreversible event. 
Pregnancy test is mandatory in women and must be performed ev-
ery month before the next dose of the medication. The contraceptive 




cessation	 of	 treatment	without	 risk	 for	 future	pregnancies.1 Some 
other	adverse	events,	with	very	low	or	absent	risk	are:	bone	alter-
ations	 (premature	 closure	 of	 the	 epiphysis,	 higher	 risk	 of	 keloids	






and 3% three cycles.1
Hormonal agents
For	 women,	 with	 or	 without	 hyperandrogenemia,	 hor-
monal	blockade	 is	useful	because	acne	 is	an	androgen-dependent	
disease.	This	is	a	safe	and	effective	alternative,	either	alone	or	asso-
ciated with topical treatments. The activity of the sebaceous gland 
- the production of sebum - depends on the activation of androgen 
receptors	 in	 the	sebocytes	by	androgens	produced	by	the	gonads,	
adrenal and sebaceous gland. Treatment reduces plasma and pe-
ripheral	concentration	of	androgens	and	production	and	qualitative	
changes	in	sebum,	reduce	colonization	of	P. acnes at pilosebaceous 
follicle.	The	most	commonly	used	drugs	that	block	receptors	and	in-
hibit	ovarian	production	are	cyproterone	acetate	and	drospirenone,	





traceptives	 (COCs)	 versus	 OABs	 concluded	 that	 both,	 compared	
with	 placebo,	 reduced	 acne	 lesions.	 OABs	 were	 superior	 after	 3	
months	of	treatment	and	COCs	were	equivalent	at	the	sixth	month,	
that	is,	COCs	may	represent	the	first-line	for	prolonged	treatments	
in	 adult	women.	 Their	 adverse	 events	 include	 nausea,	 headache,	
mastodynia,	 sporadic	 bleeding	 and	 decreased	 libido.	 Benefits	 in-
clude	protection	against	ovarian	and	endometrial	cancer,	reduction	
of	dysmenorrhea,	iron	deficiency	anemia,	and	pelvic	inflammatory	
disease. Incidence of venous thromboembolism in young women 
is	 low;	however,	there	is	an	increase	of	0.05%	to	0.1%	with	COCs.	
They	should	be	avoided	in	smokers,	family	history	or	risk	of	deep	
venous	 thrombosis	and	cardiovascular	disease.	 Insulin	 sensitizers	
(e.g.	metformin)	are	indicated	only	in	polycystic	ovary	syndrome,	





woman with adrenal hyperandrogenism. The most commonly used 




Manual	 comedone	 extraction,	 unclogs	 follicular	 infundib-
ulum,	 facilitates	 the	 penetration	 of	 topical	 products,	 providing	 a	
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positive	 impact	on	 the	quality	of	 life	 and	avoiding	 improper	ma-
nipulation of lesions by the patient and/or inexperienced people. 
The	electrocauterization	of	closed	macro-comedones	should	be	su-
perficial	to	decrease	the	risk	of	scars.	It	is	useful	to	avoid	the	evolu-
tion to papular-pustular lesions and manipulation. The intralesional 
corticosteroid	injection	(triamcinolone	acetonide)	is	used	in	isolated	
nodules,	accelerating	their	regression	and	relieving	pain,	as	well	as	
in	 hypertrophic	 and	 keloid	 scars,	with	 total	 or	 partial	 regression.	
Drainage	of	cysts	and	abscesses	 is	done	when	there	 is	fluctuation	
in	 lesions	and	 should	be	associated	with	oral	 antibiotics.	 Superfi-
cial	 chemical	 peels	 (20%	 to	 30%	 salicylic	 acid,	 Jessner’s	 solution,	
10%	trichloroacetic	acid	or	20%	aqueous	solution,	and	70%	glycolic	
acid	 in	 gel,	with	partially	 buffered	pH)	 are	useful	 for	 comedonal	
and	 papular-pustular	 acne	 by	 their	 keratolytic	 action.	 All	 cause	
temporary	burning,	erythema	and	desquamation	after	3	to	5	days	





Light or LED - light emitting diode - blue or red exhibits 
photochemical,	 immunomodulatory	and	anti-inflammatory	effects	
faster than drug treatment and can be associated in the early stag-
es improving adherence to treatment. Photo-pneumatic therapy is 
a relatively new technology in the treatment of acne and appears 
to be effective in moderate cases combining photochemical effects 
with mechanical extrusion of comedones in addition to a light pho-
tothermal	effect.	Among	the	laser	or	light	procedures,	the	most	evi-
dence	is	photodynamic	therapy,	which	uses	a	photosensitizer,	such	
as	 aminolevulinic	 acid,	 applied	 for	 1	 to	 3	 hours,	 during	which	 it	







seborrhea),	 salicylic	 acid-based	 dermocosmetics,	 lipo-hydroxy-ac-
ids,	retinol,	glycolic	acid	(in	low	concentrations)	and	nicotinamide	
may	be	sufficient	to	control	the	disease.	Moisturizers	help	to	reduce	
adverse events of topical products and dryness due to oral isotreti-
noin,	by	improving	the	epidermal	barrier	that	is	essential	to	prevent	
and	 reduce	 inflammation.	 Sunscreens	 and	 nicotinamide	 prevent	
postinflammatory	 hyperpigmentation.	 Cleansing	 agents	 suitable	




ment,	 reduce	adverse	events,	decrease	 the	need	for	 topical	antibi-
otics and improve adherence/compliance to the therapeutic plan.4
Treatment of acne scars is a different chapter and will be 
treated separately. q
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